Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke. A preliminary feasibility and safety study in a non-human primate model

Neuroradiology

Volumn 47, Issue 11, 2005, Pages 845-854

  Qureshi, Adnan I ^d   Suri, M Fareed K ^a   Ali, Zulfiqar ^a   Ringer, Andrew J ^a   Boulos, Alan S ^a   Nakada, Marian T ^c   Alberico, Ronald A ^b   Martin, Lisa B E ^b   Guterman, Lee R ^a   Hopkins, L Nelson ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c CENTOCOR INC   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Antiplatelet agents; Ischemic stroke; Magnetic resonance imaging; Primates; Thrombolysis

Indexed keywords

ABCIXIMAB; PLACEBO; RETEPLASE; RETEVASE;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; CAROTID ARTERY; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; FEASIBILITY STUDY; FIBRINOLYTIC THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RECANALIZATION; RHESUS MONKEY; THROMBOGENESIS;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; CEREBROVASCULAR ACCIDENT; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; FIBRINOLYTIC AGENTS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRALESIONAL; INTRACRANIAL THROMBOSIS; MACACA FASCICULARIS; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOM ALLOCATION; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 28144439355     PISSN: 00283940     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00234-003-1097-7     Document Type: Article

References (36)

1. Antman EM, Giugliano RP, Gibson CM, et al (1999) Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 99:2720-2732 10351964
2. Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN (2000) Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part I - Pathophysiological and pharmacological features. Neurosurgery 46:1344-1359 10.1097/ 00006123-200006000-00012
3. Bihour C, Durrieu-Jais C, Besse P, Nurden P, Nurden AT (1995) Flow cytometry reveals activated GP IIb-IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction. Blood Coagul Fibrinolysis 6:395-410 8589205
4. Fitzgerald DJ, Catella F, Roy L, FitzGerald GA (1988) Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 77:142-150 3275505
5. Coller BS (1997) GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 78:730-735 9198247
6. Lee VM, Burdett NG, Carpenter A, et al (1996) Evolution of photochemically induced focal cerebral ischemia in the rat. Magnetic resonance imaging and histology. Stroke 27:2110-2118 8898824
7. Moseley ME, Kucharczyk J, Mintorovitch J, et al (1990) Diffusion-weighted MR imaging of acute stroke: Correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR 11:423-942 2161612
8. Connolly TM, Condra C, Feng DM, et al (1994) Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemost 72:627-633 7878643
9. Weiner EJ, Stucchi AF, Foxall TL, Shwaery GT, Yoganathan S, Nicolosi RJ (1994) The effects of doxazosin on platelet aggregation, platelet adhesion and blood coagulation in cynomolgus monkeys. Atherosclerosis 107:35-44 10.1016/0021-9150(94)90139-2
10. Deitch JS, Williams JK, Adams MR, et al (1998) Effects of beta3-integrin blockade (c7E3) on the response to angioplasty and intra-arterial stenting in atherosclerotic nonhuman primates. Arterioscler Thromb Vasc Biol 18:1730-1737 9812911
11. Meden P, Overgaard K, Sereghy T, Boysen G (1993) Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model. J Neurol Sci 119:209-216 10.1016/0022-510X(93)90136-M
12. Shuaib A, Yang Y, Li Q, Siddiqui MM, Kalra J (1998) Intraarterial urokinase produces significant attenuation of infarction volume in an embolic focal ischemia model. Exp Neurol 154:330-335 10.1006/ exnr.1998.6925
13. Ringer AJ, Guterman LR, Hopkins L N (2001) Site-specific thromboembolism: A novel animal model for stroke. 50th Annual Meeting of the Congress of Neurological Surgeons, San Antonio, Texas
14. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587 10.1056/NEJM199512143332401
15. Neuhaus KL, von Essen R, Vogt A, et al (1994) Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: Results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). J Am Coll Cardiol 24:55-60 8006283
16. Tebbe U, von Essen R, Smolarz A, et al (1993) Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol 72:518-524 10.1016/0002-9149(93)90345-D
17. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators (1997) A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 337:1118-1123 10.1056/ NEJM199710163371603
18. Qureshi AI, Ali Z, Suri MF, et al (2001) Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery 49:41-48 10.1097/00006123-200107000-00006
19. Qureshi AI, Suri MF, Shatla AA, et al (2000) Intraarterial recombinant tissue plasminogen activator for ischemic stroke: An accelerating dosing regimen. Neurosurgery 47:473-476 10942026
20. Boehringer Mannheim GmbH. Retavase-reteplase recombinant (1997) Product monograph
21. Martin U, Kaufmann B, Neugebauer G (1999) Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective. Clin Pharmacokinet 36:265-276 10320949
22. Noble S, McTavish D (1996) Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs 52:589-605 8891469
23. Wooster MB, Auzier AB: Reteplase (1999): a new thrombolytic for the treatment of acute myocardial infarction. Ann Pharmacother 33:318-324 10.1345/aph.18006
24. The Abciximab in Ischemic Stroke Investigators (2000) Abciximab in acute ischemic stroke: A randomized, double-blind, placebo- controlled, dose-escalation study. Stroke 31:601-609 10700492
25. de Lemos JA, Antman EM, Gibson CM, et al (2000) Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 101:239-243 10645918
26. Koch KC, vom DJ, Kleinhans E, (1999) Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. J Am Coll Cardiol 33:998-1004 10.1016/S0735-1097(98)00659-7
27. Gawaz M, Neumann FJ, Dickfeld T, et al (1997) Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: Implications for reperfusion in acute myocardial infarction. Circulation 96:1809-1818 9323066
28. Murphy JF, Bordet JC, Wyler B, et al (1994) The vitronectin receptor (alpha v beta 3) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells. Biochem J 304 (Pt 2):537-542 7528011
29. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK (1997) 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 17:528-535 9102172
30. Furlan A, Higashida R, Wechsler L (1999) Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282:2003-2011 10.1001/jama.282.21.2003
31. Harrington RA, Ohman EM, Sigmon KN, et al (1995) Intensity of inhibition of the platelet glycoprotein IIb/IIIa receptor differs among disease states. Circulation 92 [Suppl I]:I-488-I-489
32. Merlini PA, Bauer KA, Oltrona L, et al (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90:61-68 8026047
33. Kleiman NS, Raizner AE, Jordan R, et al (1995) Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 26:1665-1671 10.1016/0735-1097(95)00391-6
34. Boyko OB, Alston SR, Fuller GN, Hulette CM, Johnson GA, Burger PC (1994) Utility of postmortem magnetic resonance imaging in clinical neuropathology. Arch Pathol Lab Med 118:219-225 8135623
35. De Groot CJ, Bergers E, Kamphorst W, et al (2001) Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: Increased yield of active demyelinating and (p) reactive lesions. Brain 124:1635-1645 10.1093/ brain/124.8.1635
36. Anderson HV, Willerson JT (1993) Thrombolysis in acute myocardial infarction. N Engl J Med 329:703-709 10.1056/NEJM199309023291006